Kiniksa Pharmaceuticals International KNSA
NASDAQ KNSA
$79.69 -3.48 (-4.18%)
As of: Oct 21, 2026 · 3:59 PM EDT

Kiniksa Pharmaceuticals International (KNSA) Receivables - Other (2022)

Updated

Kiniksa Pharmaceuticals International (KNSA) recorded Receivables - Other of $7.66 million in Q4 2022.

Analysis

Kiniksa Pharmaceuticals International (KNSA) Receivables - Other (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Kiniksa Pharmaceuticals International 6.18 Bn 4.92 Bn 220.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 7.66 Mn
API Access

Kiniksa Pharmaceuticals International Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=KNSA&period=max&api_key=YOUR_API_KEY